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The authors retrospectively aimed to determine which of the following three scenarios,
related to DCIS entry into BRCAPRO, predicted BRCA mutation status more accurately:
(1) DCIS as an invasive breast cancer (IBC) entered using the actual age of diagnosis, (2)
DCIS as IBC entered with 10 years added to the actual age of diagnosis, and (3) DCIS
entered as no cancer. Of the 85 DCIS patients included in the study, 19% (n = 16) tested
positive for a BRCA mutation, and 81% (n = 69) tested negative. DCIS patients who
tested positive for a BRCA mutation had a higher BRCAPRO risk estimation (34.61%)
than patients who tested negative (11.4%) when DCIS was entered at the actual age of
diagnosis. When DCIS was entered with 10 years added to the actual age at diagnosis,
the BRCAPRO estimate was still higher amongst BRCA positive patients (25.4%) than
BRCA negative patients (7.1%). When DCIS was entered as no cancer, the BRCAPRO
estimate remained higher among BRCA positive patients (2.56%) than BRCA negative
patents (1.98%). In terms of accuracy of BRCA positivity, there was no statistically
significant difference between DCIS at age at diagnosis, DCIS at 10 years later than age
at diagnosis, and DCIS entered as no cancer (AUC = 0.77, 0.784, 0.75, respectively:
p = 0.60). Our results indicate that regardless of entry approach into BRCAPRO, there
were no significant differences in predicting BRCA mutation in patients with DCIS.
Keywords: ductal carcinoma in situ (DCIS), genetics, gene, BRCA1, genes, BRC, BRCAmutation status, BRCAPRO
INTRODUCTION
It has been shown that hereditary predisposition constitutes a major risk factor for the development
of breast cancer (BC). Five to ten percent of BC is caused by inheritable gene mutations (Seeber and
Driscoll, 2004). The BRCA1 and BRCA2 (BRCA) genes account for a high percentage of hereditary
breast and ovarian cancer (Seeber and Driscoll, 2004). Carriers of one of the these mutations have
a 43–84% risk of developing BC in their lifetime, and up to 65% risk for a contralateral BC (Ford
et al., 1998; Chen et al., 2006).
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Understanding one’s risk for testing positive for a genetic
mutation has clinical and personal implications, therefore
accurate risk assessment is crucial. Several genetic risk assessment
models have been used to predict an individual’s likelihood
of possessing a BRCA gene mutation. More specifically,
the BRCAPRO model is a risk assessment tool part of
the CancerGene program. It utilizes Bayes Mendel analysis
and ultimately determines those that are at an increased
risk of developing breast, ovarian and other cancer types.
The BRCAPRO model has been shown to be an accurate
model for determining the probability of carrying a genetic
mutation (Berry et al., 2002). This model incorporates personal
and family history information to determine the probability
of a BRCA gene mutation. The analysis incorporates the
number of first and second degree relatives along with the
tumor histories of the patient and the family members.
However, the incorporated tumor history only includes the
invasive diagnoses and does not include the pre-invasive
lesions.
Ductal carcinoma in situ (DCIS) accounts for 25% of all newly
diagnosed BC in the United States (American Cancer Society,
2015). It is the most common (80–90%) type of in situ carcinoma
in the breast, and is a direct precursor to most invasive breast
cancer (IBC) (Allred, 2010). Long-term follow-up studies have
shown the natural history of untreated DCIS as developing into
an IBC (Page et al., 1982, 1995; Eusebi et al., 1994; Erbas et al.,
2006). The risk of developing IBC after a diagnosis of DCIS
ranges from 14 to 60% at 10 years follow-up (Burstein et al.,
2004).
Historically, a diagnosis of DCIS was considered a pre-
cancerous lesion and was not entered into the BRCAPRO model
(Parmigiani et al., 1998). Currently, DCIS is not specifically
accounted for in the BRCAPRO model and there are no
standardized guidelines of how DCIS should be entered into
the Cancer Gene program. The practice varies among genetic
counselors in various parts of the country depending on the
clinical training site. Since there no standard guidelines to date,
and given the natural course of DCIS progression to IBC in 10
years (Burstein et al., 2004), we used the same criteria established
in our institution by adding 10 years to the age of diagnosis
(Bayraktar et al., 2012).
It has been previously reported that a BRCA gene mutations
have been identified in individuals with DCIS. Hwang et al.
reported 37% of individuals with DCIS (with or without
IBC) were determined to possess a BRCA gene mutation
(Hwang et al., 2007). In addition, Bayraktar et al. identified
a 27% BRCA positivity rate amongst individuals with pure
DCIS (Bayraktar et al., 2012). Finally, Claus et al. (2005),
determined individuals with DCIS had mutation rates similar
to those with IBC. Therefore, the different approaches of
DCIS entry into the BRCAPRO model may not allow for
an accurate risk estimation of a BRCA mutation probability
amongst patients with DCIS. Furthermore, recent NCCN
Clinical Practice Guidelines In Oncology (NCCN Guidelines R©)
recommend referral for genetic counseling and consideration
of BRCA testing for patients with DCIS; and therefore,
accurately assessing these patients for genetic testing has become
even more important (NCCN Clinical Practice Guidelines,
2015 1).
In the present study, we aimed to determine which of the
following three scenarios, related to DCIS entry into BRCAPRO,
predicted BRCAmutation status more accurately: (1) DCIS as an
IBC entered using the actual age of diagnosis, (2) DCIS as an IBC
entered with 10 years added to the age of diagnosis, and (3) DCIS
entered as no cancer.
METHODS
Women with a diagnosis of DCIS who were referred for genetic
testing were included in this study. Each participant was either
self- or physician-referred to genetic counseling between 2003
and 2011. This study included only patients with DCIS. Any
patients with invasive or micro-invasive BC, identified either at
time of biopsy or after tumor removal surgery, were excluded.
Men were also excluded given that the BRCAPRO model
values male BC significantly higher than female BC. Eighty
five women were retrospectively identified and received genetic
testing. Patients were identified from a prospectively maintained
research database, and their characteristics were obtained after
institutional review board approval at The University of Texas
MD Anderson Cancer Center. All pathologic specimens were
reviewed by a dedicated breast pathologist at our institution and
all patients underwent routine staging workup.
The likelihood of carrying a BRCA mutation was
calculated using The University of Texas Southwestern
Medical Center at Dallas CancerGene software, version 5.1
(http://www4.utsouthwestern.edu/breasthealth/cagene/). The
BRCAPRO model is a part of the CancerGene software. The
BRCAPRO risk is derived through Bayesian probability model
taking into account the patients 1st and 2nd degree relatives, age
of diagnosis of breast and/or ovarian cancer, ages of unaffected
family members (Ready et al., 2009). Themutation frequency and
penetrance estimates are derived from BC Linkage Consortium
data. Non-carrier incidence rates are derived from SEER data
with those with BRCA mutations subtracted out.
BRCAPRO risk estimations were calculated for each patient
using the three scenarios. The first estimate was calculated by
entering the patient’s DCIS as an IBC at their current age of
diagnosis. The second estimate was calculated entering DCIS as
an IBC with 10 years added to the actual age of diagnosis. The
third estimation was calculated with the patient’s DCIS entered
as no cancer.
Variables entered into the BRCAPRO model for each patient
included: gender; current age or age of death; any diagnosis
of BC, second primary BC, and ovarian cancer; and age at
diagnosis of those cancers; tumor markers (estrogen receptor-ER
and progesterone receptor-PR), history of oophorectomy, family
1Referenced from the NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines R©). © National Comprehensive Cancer Network, Inc., 2015. All rights
reserved. Accessed (May 13, 2015). To view the most recent and complete version
of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE
CANCER NETWORK R©, NCCN R©, NCCN GUIDELINES
R©
, and all other
NCCN Content are trademarks owned by the National Comprehensive Cancer
Network, Inc.
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history of 1st and 2nd degree relatives with breast and ovarian
cancer, race, and Ashkenazi Jewish (AJ) ancestry. For this study,
history of oophorectomy was used only if the procedure occurred
prior to diagnosis of DCIS. This was to limit identifying those
individuals that might have undergone this procedure due to
their cancer diagnosis or BRCA mutation status.
Patients were categorized into two groups; age of diagnosis
<40 and≥40. This was done to account for adding 10 years to the
age of diagnosis as a part of our analysis. Within the BRCAPRO
calculation, individuals diagnosed with BC age 50 and older are
no longer considered to have an early onset of BC.
Entry of information into the BRCAPRO model was
standardized and limited to only two study staff members to
avoid any discrepancies in how the information was entered.
One individual conducted the initial entry and obtained risk
estimations. The second staff member performed quality control
of the information by entering the variables separately and
determined if the same risk estimations were the same. If any
information was missing for a patient it was entered into the
BRCAPRO model as unknown or not included in the risk
assessment.
Statistical Analysis
Two sample t-test or analysis of variance (ANOVA) (Snedecor
and Cochoran, 1980) were used for the comparison of BRCAPRO
between patient groups such as BRCA positive vs. BRCA
negative. Three BRCAPRO scores were obtained for each patient
as previously defined. The area under the receiver operating
characteristic (ROC) curve (AUC) was calculated to evaluate
model discrimination (Hosmer and Lemeshow, 2000). A 2-
sided p-value of 0.05 was considered statistically significant. SAS
version 9.2 and S-Plus version 8.04 was used to carry out the
computations for all analyses.
RESULTS
Table 1 outlines demographic and clinical characteristics. Of the
85 DCIS patients included in the study 19% (n = 16) tested
positive for a BRCA mutation, 81% (n= 69) and tested negative.
The mean BRCAPRO probability when DCIS was entered at
presenting age of diagnosis was 15 (Range= 0–97) vs. 10 (Range
= 0–89.9) when calculated 10 years later and 2 (Range = 0–35)
when entered as no cancer.
We conducted three separate univariate analyses comparing
BRCAPRO at actual age of diagnosis, at 10 years added to
the actual age of diagnosis, and DCIS as no cancer. The first
univariate analysis (Table 2) comparing BRCAPRO at age of
diagnosis by patient characteristics indicated the patients who
are BRCA positive had significantly higher BRCAPRO scores
at age of diagnosis than those who are BRCA negative (p =
0.001). Patients with ER-negative DCIS had higher BRCAPRO
scores than those who were ER-positive (p = 0.005), and
patients with two or more first degree relatives with BC had
the highest BRCAPRO scores, compared to those with one or
no relatives with BC (p = 0.0002). The more relatives with BC,
the higher the BRCAPRO scores was when compared to those
TABLE 1 | Patient characteristics and demographics.
Variable Category Counts Percent
AVERAGE AGE OF DIAGNOSIS (RANGE) 47 (30–75)
BRCA mutation status Negative 69 81.2
Positive 16 18.8
Age of diagnosis (by
group)
≤40 30 35.3
>40 55 64.7
BRCAPRO estimations
(average)
At age of DCIS
diagnosis
0–97 15
Addition of 10
years to age of
DCIS diagnosis
0–89.9 10
As No Cancer 0–35 2
Race White 72 84.7
African–
American
3 3.5
Hispanic 5 5.9
Asian 5 5.9
Ashkenazi Jewish (AJ)
Ancestry
Unknown 1 1.2
No 77 90.6
Yes 7 8.2
FAMILY HISTORY CHARACTERISTICS
First degree relatives
with BC
0 47 55.3
1 30 35.3
2 8 9.4
Second degree
relatives with breast
cancer
0 28 32.9
1 37 43.5
2 20 23.5
Total number of
relatives with BC
0 9 10.6
1 15 17.7
2 20 23.5
3 21 24.7
4 20 23.5
First degree relatives
with ovarian cancer
0 80 94.1
1 5 5.9
Second degree
relatives with ovarian
cancer
0 77 90.6
1 6 7.1
2 2 2.4
Total number of
relatives with ovarian
cancer
0 68 80.0
≥1 17 20.0
Bilateral salphingo
oophorectomy (BSO)
Unknown 3 3.5
No 64 75.3
Yes 18 21.2
TUMOR CHARACTERISTICS
Nuclear grade I 6 7.1
II 35 41.2
III 34 40.0
Unknown 10 11.8
Estrogen receptor (ER) Negative 11 12.9
Positive 59 69.4
Unknown 15 17.7
Progesteron receptor
(PR)
Negative 18 21.2
Positive 51 60.0
Unknown 16 18.8
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with less with BC (p = 0.00056). AJ ancestry, bilateral salpingo-
oophorectomy (BSO), grade, family history of ovarian cancer
were not significantly associated with an increased BRCAPRO
scores when DCIS was entered at actual age of diagnosis.
The second univariate analysis (Table 3) comparing
BRCAPRO scores, using DCIS entered with 10 years added
to the actual age of diagnosis, by patient’s characteristics
indicated several significant findings. Consistent with Table 2
results, patients who were BRCA positive had significantly higher
BRCAPRO scores than those who were BRCA negative (p <
0.0001). Patients with two or more first degree relatives with
BC had the highest BRCAPRO scores when 10 years was added
to the actual age of diagnosis, compared to those with one or
no relatives with BC (p = 0.0002). Patients with more relatives
with BC had the highest BRCAPRO scores when 10 years was
added to the actual age of diagnosis, compared to those with less
relatives with BC (p= 0.008).
The third univariate analysis (Table 4) comparing BRCAPRO
with DCIS entered as no cancer revealed patients who were
BRCA positive had significantly higher BRCAPRO scores than
those who were BRCA negative (p= 0.003). Patients with two or
more first degree relatives with BC had the highest BRCAPRO,
compared to those with one or no relatives with BC (p< 0.0001).
Additionally, patients with more relatives with BC had the
highest BRCAPRO scores compared to those with less relatives
with BC (p= 0.0025).
Finally, for validation we obtained BRCAPRO prediction
by calculating area under the receiver operating characteristics
(AUC), sensitivity, and specificity. Figure 1 indicates, in terms
of accuracy of BRCA positivity, BRCAPRO at age of diagnosis
[AUC = 0.77 (95% CI: 0.64–0.90)], BRCAPRO with diagnosis
10 years later [0.78 (95% CI: 0.66–0.91)], and BRCAPRO with
DCIS entered as no cancer [0.75 (95 % CI: 0.64–0.87)] were
not statically significant (p = 0.60) for the comparison of
three curves.
DISCUSSION
The present study determined that patients who are BRCA
positive had a higher BRCAPRO score than those who were
negative whether DCIS was entered as actual age of diagnosis,
or when 10 years was added to the actual age of diagnosis, or
as no cancer. To our knowledge, this study uniquely examines
the variations of DCIS entry in the BRCAPRO model, and may
suggest that regardless of how DCIS is entered, there were no
significant differences in predicting BRCA mutation status.
Consistent with our findings, Bayraktar et al. (2012) found
among patients with DCIS, those who had a family history of
OC or who had BRCAPRO scores ≥10% had a higher rate of
BRCA positivity regardless of age at diagnosis. Collectively, these
findings suggest that patients with DCIS may be treated similarly
to patients with IBC when entered into the BRCAPRO model to
determine BRCA mutation probability.
Moreover, Hwang et al. (2007) examined 129 BRCA-positive
and 269 BRCA negative women for likelihood of BRCA
mutation. BRCA positive patients have an earlier average age of
TABLE 2 | Comparisons of BRCAPRO at age of diagnosis by patient’s
characteristics.
Variable Group n mean std p value
BRCA Negative 69 11.40 19.40 0.001
Positive 16 34.61 33.01
AJ ancestry No 77 15.7 25.08 0.078
Yes 7 18.4 12.84
Yes 18 19.60 29.84
First degree relatives
with BC
0 47 9.17 18.55 0.0002
1 30 17.79 22.98
2 8 46.91 33.54
Second degree
relatives with BC
0 6 3.97 3.27 0.815
1 37 15.92 22.3
2 20 21.49 31.77
Unknown 22 13.53 22.05
Total relatives with
BC
0 9 5.07 6.81 0.0056
1 15 5.94 11.45
2 20 15.40 19.57
3 21 16.14 20.19
4 20 27.94 24.26
First degree relatives
with ovarian cancer
0 80 16.09 24.57 0.982
1 5 10.62 16.65
Second degree
relatives with ovarian
cancer
1 6 32.42 39.57 0.511
2 2 50.30 63.78
Total relatives with
ovarian cancer
0 68 12.60 20.60 0.103
≥1 17 28.44 32.70
BSO No 64 13.39 20.62 0.824
Yes 18 19.60 29.84
ER status Negative 11 16.83 26.78 0.005
Positive 59 12.73 21.56
PR status Negative 18 13.79 24.09 0.311
Positive 51 13.34 22.08
ER/PR ER negative-PR
negative
11 16.83 26.78 0.098
ER positive-PR
negative
7 9.03 20.16
ER positive-PR
positive
51 13.34 22.08
Nuclear grade I 6 4.58 4.69 0.706
II 35 13.72 22.97
III 34 15.47 21.62
diagnosis for both DCIS and invasive BC than BRCA negative
patients. The conclusion of their study reinforces the assertion
that DCIS and IBC may treated similarly when using BRCA risk
assessments models.
These studies along with our findings, suggest there are no
significant differences seen in the BRCAPRO risk estimation
when DCIS is entered into the BRCAPRO model of the
CancerGene program at current age of diagnosis, or 10 years
later, or as no a cancer. Furthermore, the most recent NCCN
Guidelines R© recommend genetic risk evaluation and genetic
testing for individuals with DCIS. This implies that IBC and
DCIS may similarly affect the probability of predicting BRCA
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TABLE 3 | Comparisons of BRCAPRO at 10 years later than age of
diagnosis by patient’s characteristics.
Variable Group n mean std p value
BRCA Negative 69 7.09 14.49 <0.0001
Positive 16 25.38 28.28
AJ ancestry No 77 10.66 19.9 0.099
Yes 7 10.41 8.54
First degree
relative with BC
0 47 5.43 13.9 0.0002
1 30 12.64 19.31
2 8 32.59 28.47
Second degree
relatives with BC
0 6 1.92 1.52 0.796
1 37 9.39 14.62
2 20 15.38 27.05
Unknown 22 10.40 19.58
Total relatives
with BC
0 9 2.38 3.09 0.008
1 15 2.33 3.9
2 20 10.63 14.31
3 21 12.56 26.59
4 20 18.14 22.29
First degree
relative with
ovarian cancer
0 80 10.98 19.58 0.750
1 5 3.32 3.93
Second degree
relatives with
ovarian cancer
1 6 24.48 35.23 0.254
2 2 42.50 54.87
Total relatives
with ovarian
cancer
0 68 8.41 15.76 0.096
≥1 17 19.02 27.89
BSO No 64 8.08 15.44 0.553
Yes 18 14.93 23.3
ER status Negative 11 13.96 24.71 0.071
Positive 59 8.1 15.89
PR status Negative 18 10.79 20.98 0.354
Positive 51 8.50 16.43
ER/PR ER
negative-PR
negative
11 13.96 24.71 0.151
ER
positive-PR
negative
7 5.81 13.49
ER
positive-PR
positive
51 8.50 16.43
Nuclear grade I 6 2.57 2.73 0.594
II 35 8.3 17.1
III 34 10.69 15.86
positivity. The insignificant differences of the AUCs may be due
to lack of statistical power despite the observed small differences
of the AUCs among the three different scenario. This along
with the NCCN guidelines, suggests the need for a study to
formally test the hypothesis that these three scenarios predict
BRCA positivity similarly. Our rationale for choosing to enter
DCIS as invasive cancer includes the followings: (1) when a DCIS
patient undergoes genetic counseling, entering the diagnosis as
TABLE 4 | Comparisons of BRCAPRO with DCIS entered as no cancer by
patient’s characteristics.
Variable Group n mean std p value
BRCA Negative 69 1.98 6.09 0.003
Positive 16 2.56 2.63
AJ ancestry No 77 2.18 5.87 0.192
Yes 7 1.34 1.16
First degree relative
with BC
0 47 0.61 1.28 <0.0001
1 30 2.00 2.94
2 8 11.05 14.93
Second degree
relatives with BC
0 6 0.20 0.20 0.429
1 37 1.73 2.92
2 20 2.95 7.63
Unknown 22 2.40 7.48
Total relatives with
BC
0 9 0.20 0.21 0.0025
1 15 0.52 1.19
2 20 1.43 2.69
3 21 3.17 7.90
First degree relative
with ovarian cancer
0 80 2.15 5.76 0.527
1 5 1.12 1.38
Second degree
relatives with
ovarian cancer
1 6 2.68 3.85 0.366
2 2 3.10 1.84
Total relatives with
ovarian cancer
0 68 2.05 6.10 0.062
≥1 17 2.23 2.91
Bilateral salpingo-
oophorectomy
(BSO)
No 64 1.75 4.78 0.287
Yes 18 1.56 2.30
ER status Negative 11 0.96 1.83 0.527
Positive 59 2.29 6.49
PR status Negative 18 1.06 2.21 0.330
Positive 51 2.46 6.90
ER/PR ER negative-PR
negative
11 0.96 1.83 0.604
ER positive-PR
negative
7 1.20 2.87
ER positive-PR
positive
51 2.46 6.90
Nuclear grade I 6 0.48 0.49 0.679
II 35 1.93 6.09
III 34 2.61 6.24
IBC will better assess the risk given the natural progression of the
disease, (2) This will help the patient further meet clinical testing
guidelines. In this sense, knowing the patient’s disease and the
BRCA risk assessment will allow for a better chance of receiving
genetic testing when deemed clinically necessary. Furthermore,
the results will enable patients to take preventive measures when
applicable.
Given the diagnosis of DCIS is increasing in the US (Tuttle
et al., 2009; Bayraktar et al., 2012), more healthcare providers
will be faced with providing accurate genetic risk assessment for
BRCA testing for these patients. We believe our study results
may provide valuable information to assist in accurate genetic
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FIGURE 1 | ROC curve for BRCAPRO with age entered as age of diagnosis or age entered as 10 years older or with DCIS entered as not a cancer in
the model when the outcome is BRCA status.
risk assessment for individuals with DCIS, and to help provide
a standard entry method into this widely used clinical model.
Since there are no currently established guidelines for entering
DCIS, our study suggests that there was no difference between the
three approaches evaluated to predict BRCA mutation: (1) DCIS
as IBC entered using the actual age of diagnosis, (2) DCIS as an
IBC entered with 10 years added to the actual age of diagnosis, or
(3) DCIS entered as no cancer. Therefore, heath care providers
could safely use the approach closest to their practice.
LIMITATIONS
The study results should be viewed in light of its limitations.
This study included patients who were referred for genetic
counseling and testing, thus may be not generalizable to all
patients with DCIS. When calculating BRCAPRO scores not all
patient characteristics were available for every patient. There are
also overall limitations of the BRCAPRO model that should be
considered. The BRCAPRO model tends to underestimate the
importance of ovarian cancer and assumes affected individuals
in a family are due to the presence of a BRCA gene mutation.
This risk model is a part of the overall genetic assessment, but it
certainly is not the only indicator for testing. Other factors such
as limited family structure, additional personal risk factors such
presence of atypia, and additional family history of other cancers
associated with gene mutation as are also considered when
deciding for genetic testing but not accounted for in the model.
There are other BRCA prediction models used for those with
BC that were not utilized for this assessment. Lastly, our sample
size was small, which results in a relatively wide 95% confidence
interval for the AUCs of the three BRCAPRO scenarios. Future
studies are needed to replicate these findings in a larger cohort.
CONCLUSION
Our findings suggest that there are no significant changes seen in
the BRCAPRO score probability when using the three different
scenarios we evaluated. Thus, a diagnosis of DCIS may be
treated similar to an IBC diagnosis at current age of diagnosis.
It may not be necessary to add 10 years to the patient’s age
of diagnosis when using the CancerGene Program. The clinical
implication of our study is to promote a more consistent and
standardized entry method for individuals with a DCIS diagnosis
in genetic oncology clinics. Future studies should be done to
determine if our outcomes are consistent using other prediction
models.
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